Top companies

ASIANPAINT - 2428.15 (-2.24%) AXISBANK - 1139.15 (0.46%) BAJAJFINSV - 1569.25 (-1.7%) BAJFINANCE - 6465.65 (-1.97%) BHARTIARTL - 1525.15 (-0.02%) BPCL - 282.4 (-1.77%) COALINDIA - 406 (-1.52%) HDFCBANK - 1741.2 (-0.06%) HEROMOTOCO - 4767.85 (-0.17%) HINDUNILVR - 2382.8 (-1.14%) ICICIBANK - 1250.55 (0.12%) INDUSINDBK - 981.45 (-1.87%) ITC - 457.15 (-2.18%) KOTAKBANK - 1737.1 (0.54%) MARUTI - 10861.45 (-0.89%) ONGC - 242.15 (-2.36%) RELIANCE - 1223 (-1.5%) SBIN - 780.75 (-2.77%) TATAMOTORS - 773.85 (-1.19%) TATASTEEL - 140.22 (0.55%) TCS - 4072.85 (0.82%) TITAN - 3178.45 (-1.43%) WIPRO - 557.15 (-0.86%)
TRENDING #Adani Enterprises Limited1 #NLC India Limited1 #Nifty 501 #Nifty Bank1

Zydus Life hits 52-week high on USFDA nod for Sacubitril and Valsartan

11 Jul , 2024   By : Debdeep Gupta


Zydus Life hits 52-week high on USFDA nod for Sacubitril and Valsartan

Shares of Zydus Lifesciences touched a 52-week high of Rs 1,203.20 in the early trade on July 11, riding on the final approval from the United States Food and Drug Administration (USFDA) to market a key drug used to treat chronic heart failure.


At 09:21 am, Zydus Lifesciences was quoting at Rs 1,178.95, down Rs 1.45, or 0.12 percent, on the BSE.


Sacubitril and Valsartan Tablets (24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg) are combinations used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization.


The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).


The group now has 399 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.


Also, the company received tentative approval from the USFDA to market Diroximel Fumarate Delayed-Release Capsules, 231 mg.


Earlier this month, the company received tentative approval from the USFDA to market Azilsartan Medoxomil Tablets, 40 mg, and 80 mg.

0 Comment


LEAVE A COMMENT


Growmudra © 2024 all right reserved

Partner With Us